Small molecule-mediated activation of the integrin CD11b/CD18 reduces inflammatory disease

Science Signaling

Volumn 4, Issue 189, 2011, Pages

  Maiguel, Dony ^a   Faridi, Mohd Hafeez ^a   Wei, Changli ^a   Kuwano, Yoshihiro ^b   Balla, Keir M ^c   Hernandez, Dayami ^a   Barth, Constantinos J ^a   Lugo, Geanncarlo ^c   Donnelly, Mary ^a   Nayer, Ali ^a   Moita, Luis F ^d   Schürer, Stephan ^a   Traver, David ^c   Ruiz, Phillip ^a   Vazquez Padron, Roberto I ^a   Ley, Klaus ^b   Reiser, Jochen ^a   Gupta, Vineet ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF LISBON   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CD11B ANTIGEN; CD18 ANTIGEN; LEUKADHERIN 1; LEUKADHERIN 2; LEUKADHERIN 3; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY M1 70; UNCLASSIFIED DRUG; CALCIUM; MAGNESIUM; MANGANESE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHEMOTAXIS; CONTROLLED STUDY; GENETIC TRANSFECTION; IMMUNOREGULATION; IN VITRO STUDY; INFLAMMATORY DISEASE; KIDNEY FUNCTION; KIDNEY INJURY; LEUKOCYTE ADHERENCE; LEUKOCYTE MIGRATION; LIGAND BINDING; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; CELL ADHESION; CELL STRAIN K 562; CYTOLOGY; DRUG EFFECT; HUMAN; INFLAMMATION; LEUKOCYTE; METABOLISM; MOLECULAR LIBRARY; NEUTROPHIL CHEMOTAXIS; PHYSIOLOGY;

RATTUS;

ANIMALS; ANTIGENS, CD11B; ANTIGENS, CD18; CALCIUM; CELL ADHESION; CHEMOTAXIS, LEUKOCYTE; HUMANS; INFLAMMATION; K562 CELLS; LEUKOCYTES; MACROPHAGE-1 ANTIGEN; MAGNESIUM; MANGANESE; MICE; RATS; SMALL MOLECULE LIBRARIES;

EID: 80052573917     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2001811     Document Type: Article

References (83)

1. M. A. Arnaout, Structure and function of the leukocyte adhesion molecules CD11/CD18. Blood 75, 1037-1050 (1990).
2. K. Ley, C. Laudanna, M. I. Cybulsky, S. Nourshargh, Getting to the site of inflammation: The leukocyte adhesion cascade updated. Nat. Rev. Immunol. 7, 678-689 (2007).
3. A. Coxon, P. Rieu, F. J. Barkalow, S. Askari, A. H. Sharpe, U. H. von Andrian, M. A. Arnaout, T. N. Mayadas, A novel role for the β2 integrin CD11b/CD18 in neutrophil apoptosis: A homeostatic mechanism in inflammation. Immunity 5, 653-666 (1996).
4. D. C. Altieri, T. S. Edgington, The saturable high affinity association of factor X to ADP-stimulated monocytes defines a novel function of the Mac-1 receptor. J. Biol. Chem. 263, 7007-7015 (1988).
5. M. H. Ginsberg, X. Du, E. F. Plow, Inside-out integrin signalling. Curr. Opin. Cell Biol. 4, 766-771 (1992).
6. R. O. Hynes, Integrins: Bidirectional, allosteric signaling machines. Cell 110, 673-687 (2002).
7. H. Jaeschke, A. Farhood, A. P. Bautista, Z. Spolarics, J. J. Spitzer, C. W. Smith, Functional inactivation of neutrophils with a Mac-1 (CD11b/CD18) monoclonal antibody protects against ischemia-reperfusion injury in rat liver. Hepatology 17, 915-923 (1993).
8. 2- leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits. Proc. Natl. Acad. Sci. U.S.A. 95, 10134-10139 (1998).
9. I. Wilson, A. M. Gillinov, W. E. Curtis, J. DiNatale, R. M. Burch, T. J. Gardner, D. E. Cameron, Inhibition of neutrophil adherence improves postischemic ventricular performance of the neonatal heart. Circulation 88, II372-II379 (1993).
10. R. W. Wilson, C. M. Ballantyne, C. W. Smith, C. Montgomery, A. Bradley, W. E. O'Brien, A. L. Beaudet, Gene targeting yields a CD18-mutant mouse for study of inflammation. J. Immunol. 151, 1571-1578 (1993).
11. A. Dove, CD18 trials disappoint again. Nat. Biotechnol. 18, 817-818 (2000).
12. J. M. Harlan, R. K. Winn, Leukocyte-endothelial interactions: Clinical trials of antiadhesion therapy. Crit. Care Med. 30, S214-S219 (2002).
13. M. Berger, J. O'Shea, A. S. Cross, T. M. Folks, T. M. Chused, E. J. Brown, M. M. Frank, Human neutrophils increase expression of C3bi as well as C3b receptors upon activation. J. Clin. Invest. 74, 1566-1571 (1984).
14. B. J. Hughes, J. C. Hollers, E. Crockett-Torabi, C.W. Smith, Recruitment of CD11b/CD18 to the neutrophil surface and adherence-dependent cell locomotion. J. Clin. Invest. 90, 1687-1696 (1992).
15. A. F. Lum, C. E. Green, G. R. Lee, D. E. Staunton, S. I. Simon, Dynamic regulation of LFA-1 activation and neutrophil arrest on intercellular adhesion molecule 1 (ICAM-1) in shear flow. J. Biol. Chem. 277, 20660-20670 (2002).
16. E. S. Molloy, L. H. Calabrese, Therapy: Targeted but not trouble-free: Efalizumab and PML. Nat. Rev. Rheumatol. 5, 418-419 (2009).
17. T. W. Kuijpers, E. P. Mul, M. Blom, N. L. Kovach, F. C. Gaeta, V. Tollefson, M. J. Elices, J. M. Harlan, Freezing adhesion molecules in a state of high-avidity binding blocks eosinophil migration. J. Exp. Med. 178, 279-284 (1993).
18. M. Semmrich, A. Smith, C. Feterowski, S. Beer, B. Engelhardt, D. H. Busch, B. Bartsch, M. Laschinger, N. Hogg, K. Pfeffer, B. Holzmann, Importance of integrin LFA-1 deactivation for the generation of immune responses. J. Exp. Med. 201, 1987-1998 (2005).
19. E. J. Park, A. Peixoto, Y. Imai, A. Goodarzi, G. Cheng, C. V. Carman, U. H. von Andrian, M. Shimaoka, Distinct roles for LFA-1 affinity regulation during T-cell adhesion, diapedesis, and interstitial migration in lymph nodes. Blood 115, 1572-1581 (2010).
20. 7 suppresses lymphocyte migration to the gut. J. Clin. Invest. 117, 2526-2538 (2007).
21. M. S. Diamond, T. A. Springer, A subpopulation of Mac-1 (CD11b/CD18) molecules mediates neutrophil adhesion to ICAM-1 and fibrinogen. J. Cell Biol. 120, 545-556 (1993).
22. J. Y. Park, M. A. Arnaout, V. Gupta, A simple, no-wash cell adhesion-based high-throughput assay for the discovery of small-molecule regulators of the integrin CD11b/CD18. J. Biomol. Screen. 12, 406-417 (2007).
23. M. H. Faridi, D. Maiguel, C. J. Barth, D. Stoub, R. Day, S. Schürer, V. Gupta, Identification of novel agonists of the integrin CD11b/CD18. Bioorg. Med. Chem. Lett. 19, 6902-6906 (2009).
24. M. H. Faridi, D. Maiguel, B. T. Brown, E. Suyama, C. J. Barth, M. Hedrick, S. Vasile, E. Sergienko, S. Schürer, V. Gupta, High-throughput screening based identification of small molecule antagonists of integrin CD11b/CD18 ligand binding. Biochem. Biophys. Res. Commun. 394, 194-199 (2010).
25. K. Ajroud, T. Sugimori, W. H. Goldmann, D. M. Fathallah, J. P. Xiong, M. A. Arnaout, Binding affinity of metal ions to the CD11b A-domain is regulated by integrin activation and ligands. J. Biol. Chem. 279, 25483-25488 (2004).
26. 2 integrin CR3 (CD11b/CD18) is essential for ligand binding. Cell 72, 857-867 (1993).
27. 2. J. Biol. Chem. 281, 37904-37912 (2006).
28. D. C. Altieri, Occupancy of CD11b/CD18 (Mac-1) divalent ion binding site(s) induces leukocyte adhesion. J. Immunol. 147, 1891-1898 (1991).
29. 2 integrins Mac-1 and LFA-1. J. Clin. Invest. 103, 97-106 (1999).
30. M. A. Arnaout, R. F. Todd III, N. Dana, J. Melamed, S. F. Schlossman, H. R. Colten, Inhibition of phagocytosis of complement C3- or immunoglobulin G-coated particles and of C3bi binding by monoclonal antibodies to a monocyte-granulocyte membrane glycoprotein (Mol). J. Clin. Invest. 72, 171-179 (1983).
31. V. Gupta, A. Gylling, J. L. Alonso, T. Sugimori, P. Ianakiev, J. P. Xiong, M. A. Arnaout, The β-tail domain (βTD) regulates physiologic ligand binding to integrin CD11b/CD18. Blood 109, 3513-3520 (2007).
32. 2 integrin by a small molecule inhibits leukocyte migration and recruitment. Biochemistry 45, 2862-2871 (2006).
33. J. L. Alonso, M. Essafi, J. P. Xiong, T. Stehle, M. A. Arnaout, Does the integrin αA domain act as a ligand for its βA domain? Curr. Biol. 12, R340-R342 (2002).
34. M. Shimaoka, C. Lu, A. Salas, T. Xiao, J. Takagi, T. A. Springer, Stabilizing the integrin αM inserted domain in alternative conformations with a range of engineered disulfide bonds. Proc. Natl. Acad. Sci. U.S.A. 99, 16737-16741 (2002).
35. 2+-complexed crystal structures. J. Cell Biol. 143, 1523-1534 (1998).
36. J. P. Xiong, R. Li, M. Essafi, T. Stehle, M. A. Arnaout, An isoleucine-based allosteric switch controls affinity and shape shifting in integrin CD11b A-domain. J. Biol. Chem. 275, 38762-38767 (2000).
37. J. O. Lee, L. A. Bankston, M. A. Arnaout, R. C. Liddington, Two conformations of the integrin A-domain (I-domain): A pathway for activation? Structure 3, 1333-1340 (1995).
38. J. O. Lee, P. Rieu, M. A. Arnaout, R. Liddington, Crystal structure of the A domain from the α subunit of integrin CR3 (CD11b/CD18). Cell 80, 631-638 (1995).
39. L. Liu, B. R. Schwartz, N. Lin, R. K. Winn, J. M. Harlan, Requirement for RhoA kinase activation in leukocyte de-adhesion. J. Immunol. 169, 2330-2336 (2002).
40. A. Huttenlocher, M. H. Ginsberg, A. F. Horwitz, Modulation of cell migration by integrin-mediated cytoskeletal linkages and ligand-binding affinity. J. Cell Biol. 134, 1551-1562 (1996).
41. S. P. Palecek, J. C. Loftus, M. H. Ginsberg, D. A. Lauffenburger, A. F. Horwitz, Integrin-ligand binding properties govern cell migration speed through cell-substratum adhesiveness. Nature 385, 537-540 (1997).
42. S. H. Zigmond, Orientation chamber in chemotaxis. Methods Enzymol. 162, 65-72 (1988).
43. T. Lämmermann, B. L. Bader, S. J. Monkley, T. Worbs, R. Wedlich-Söldner, K. Hirsch, M. Keller, R. Förster, D. R. Critchley, R. Fässler, M. Sixt, Rapid leukocyte migration by integrin-independent flowing and squeezing. Nature 453, 51-55 (2008).
44. K. T. Stroupe, D. A. Morrison, M. A. Hlatky, P. G. Barnett, L. Cao, C. Lyttle, D. M. Hynes, W. G. Henderson; Investigators of Veterans Affairs Cooperative Studies Program #385 (AWESOME: Angina With Extremely Serious Operative Mortality Evaluation), Cost-effectiveness of coronary artery bypass grafts versus percutaneous coronary intervention for revascularization of high-risk patients. Circulation 114, 1251-1257 (2006).
45. Y. Wang, M. Sakuma, Z. Chen, V. Ustinov, C. Shi, K. Croce, A. C. Zago, J. Lopez, P. Andre, E. Plow, D. I. Simon, Leukocyte engagement of platelet glycoprotein Ibα via the integrin Mac-1 is critical for the biological response to vascular injury. Circulation 112, 2993-3000 (2005).
46. -/- mice reveals a role for inflammation in vascular repair after angioplasty. J. Clin. Invest. 105, 293-300 (2000).
47. E. E. Gabeler, R. van Hillegersberg, R. G. Statius van Eps, W. Sluiter, E. J. Gussenhoven, P. Mulder, H. van Urk, A comparison of balloon injury models of endovascular lesions in rat arteries. BMC Cardiovasc. Disord. 2, 16 (2002).
48. T. Springer, G. Galfré, D. S. Secher, C. Milstein, Mac-1: A macrophage differentiation antigen identified by monoclonal antibody. Eur. J. Immunol. 9, 301-306 (1979).
49. T. Tang, A. Rosenkranz, K. J. Assmann, M. J. Goodman, J. C. Gutierrez-Ramos, M. C. Carroll, R. S. Cotran, T. N. Mayadas, A role for Mac-1 (CDIIb/CD18) in immune complex-stimulated neutrophil function in vivo: Mac-1 deficiency abrogates sustained Fcg receptor-dependent neutrophil adhesion and complement-dependent proteinuria in acute glomerulonephritis. J. Exp. Med. 186, 1853-1863 (1997).
50. A. S. De Vriese, K. Endlich, M. Elger, N. H. Lameire, R. C. Atkins, H. Y. Lan, A. Rupin, W. Kriz, M. W. Steinhausen, The role of selectins in glomerular leukocyte recruitment in rat anti-glomerular basement membrane glomerulonephritis. J. Am. Soc. Nephrol. 10, 2510-2517 (1999).
51. S. A. Renshaw, C. A. Loynes, D. M. Trushell, S. Elworthy, P. W. Ingham, M. K. Whyte, A transgenic zebrafish model of neutrophilic inflammation. Blood 108, 3976-3978 (2006).
52. J. L. Dunne, R. G. Collins, A. L. Beaudet, C. M. Ballantyne, K. Ley, Mac-1, but not LFA-1, uses intercellular adhesion molecule-1 to mediate slow leukocyte rolling in TNF-α-induced inflammation. J. Immunol. 171, 6105-6111 (2003).
53. K. Yonekawa, J. M. Harlan, Targeting leukocyte integrins in human diseases. J. Leukoc. Biol. 77, 129-140 (2005).
54. D. Cox, M. Brennan, N. Moran, Integrins as therapeutic targets: Lessons and opportunities. Nat. Rev. Drug Discov. 9, 804-820 (2010).
55. M. Allison, PML problems loom for Rituxan. Nat. Biotechnol. 28, 105-106 (2010).
56. A. Czuchra, H. Meyer, K. R. Legate, C. Brakebusch, R. Fässler, Genetic analysis of β1 integrin "activation motifs" in mice. J. Cell Biol. 174, 889-899 (2006).
57. Z. Zou, A. A. Schmaier, L. Cheng, P. Mericko, S. K. Dickeson, T. P. Stricker, S. A. Santoro, M. L. Kahn, Negative regulation of activated α2 integrins during thrombopoiesis. Blood 113, 6428-6439 (2009).
58. S. D. Wright, P. E. Rao, W. C. Van Voorhis, L. S. Craigmyle, K. Iida, M. A. Talle, E. F. Westberg, G. Goldstein, S. C. Silverstein, Identification of the C3bi receptor of human monocytes and macrophages by using monoclonal antibodies. Proc. Natl. Acad. Sci. U.S.A. 80, 5699-5703 (1983).
59. 2+ binding epitope on leukocyte integrin α subunits. EMBO J. 8, 3759-3765 (1989).
60. N. Faust, F. Varas, L. M. Kelly, S. Heck, T. Graf, Insertion of enhanced green fluorescent protein into the lysozyme gene creates mice with green fluorescent granulocytes and macrophages. Blood 96, 719-726 (2000).
61. V. Gupta, HTS identification of compounds that enhance the binding of CD11b/CD18 to fibrinogen via a luminescence assay. PubChem BioAssay AID 1499 (2009).
62. L. Y. Chen, J. J. Shieh, B. Lin, C. J. Pan, J. L. Gao, P. M. Murphy, T. F. Roe, S. Moses, J. M. Ward, E. J. Lee, H. Westphal, B. C. Mansfield, J. Y. Chou, Impaired glucose homeostasis, neutrophil trafficking and function in mice lacking the glucose-6-phosphate transporter. Hum. Mol. Genet. 12, 2547-2558 (2003).
63. W. Bergmeier, T. Goerge, H. W. Wang, J. R. Crittenden, A. C. Baldwin, S. M. Cifuni, D. E. Housman, A. M. Graybiel, D. D. Wagner, Mice lacking the signaling molecule CalDAG-GEFI represent a model for leukocyte adhesion deficiency type III. J. Clin. Invest. 117, 1699-1707 (2007).
64. K. Szczur, H. Xu, S. Atkinson, Y. Zheng, M. D. Filippi, Rho GTPase CDC42 regulates directionality and random movement via distinct MAPK pathways in neutrophils. Blood 108, 4205-4213 (2006).
65. P. Friedl, E. B. Bröcker, Reconstructing leukocyte migration in 3D extracellular matrix by time-lapse videomicroscopy and computer-assisted tracking. Methods Mol. Biol. 239, 77-90 (2004).
66. C. H. Yoon, J. Hur, K. W. Park, J. H. Kim, C. S. Lee, I. Y. Oh, T. Y. Kim, H. J. Cho, H. J. Kang, I. H. Chae, H. K. Yang, B. H. Oh, Y. B. Park, H. S. Kim, Synergistic neovascularization by mixed transplantation of early endothelial progenitor cells and late outgrowth endothelial cells: The role of angiogenic cytokines and matrix metalloproteinases. Circulation 112, 1618-1627 (2005).
67. 2. J. Immunol. 181, 3609-3619 (2008).
68. R. Li, M. A. Arnaout, Functional analysis of the β2 integrins. Methods Mol. Biol. 129, 105-124 (1999).
69. 2 subunit reveals regions that become exposed upon receptor activation. J. Immunol. 166, 5629-5637 (2001).
70. J. P. Xiong, T. Stehle, S. L. Goodman, M. A. Arnaout, New insights into the structural basis of integrin activation. Blood 102, 1155-1159 (2003).
71. α; formerly gp 110), a surface glycoprotein associated with neutrophil adhesion. J. Clin. Invest. 74, 1280-1290 (1984).
72. C. W. Smith, S. D. Marlin, R. Rothlein, C. Toman, D. C. Anderson, Cooperative interactions of LFA-1 and Mac-1 with intercellular adhesion molecule-1 in facilitating adherence and transendothelial migration of human neutrophils in vitro. J. Clin. Invest. 83, 2008-2017 (1989).
73. J. D. Griffin, O. Spertini, T. J. Ernst, M. P. Belvin, H. B. Levine, Y. Kanakura, T. F. Tedder, Granulocyte-macrophage colony-stimulating factor and other cytokines regulate surface expression of the leukocyte adhesion molecule-1 on human neutrophils, monocytes, and their precursors. J. Immunol. 145, 576-584 (1990).
74. Kip1 safeguards against inflammatory injury. Nat. Med. 4, 575-580 (1998).
75. V. Ophascharoensuk, J. W. Pippin, K. L. Gordon, S. J. Shankland, W. G. Couser, R. J. Johnson, Role of intrinsic renal cells versus infiltrating cells in glomerular crescent formation. Kidney Int. 54, 416-425 (1998).
76. G. O. Ahn, D. Tseng, C. H. Liao, M. J. Dorie, A. Czechowicz, J. M. Brown, Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment. Proc. Natl. Acad. Sci. U.S.A. 107, 8363-8368 (2010).
77. C. Faul, M. Donnelly, S. Merscher-Gomez, Y. H. Chang, S. Franz, J. Delfgaauw, J. M. Chang, H. Y. Choi, K. N. Campbell, K. Kim, J. Reiser, P. Mundel, The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat. Med. 14, 931-938 (2008).
78. R. Boxio, C. Bossenmeyer-Pourié, N. Steinckwich, C. Dournon, O. Nüsse, Mouse bone marrow contains large numbers of functionally competent neutrophils. J. Leukoc. Biol. 75, 604-611 (2004).
79. C. Nüsslein-Volhard, Zebrafish: A Practical Approach (Oxford Univ. Press, Oxford, UK, 2002).
80. L. I. Zon, R. T. Peterson, In vivo drug discovery in the zebrafish. Nat. Rev. Drug Discov. 4, 35-44 (2005).
81. M. H. Faridi, D. Maiguel, C. J. Barth, D. Stoub, R. Day, S. Schürer, V. Gupta, Identification of novel agonists of the integrin CD11b/CD18. Bioorg. Med. Chem. Lett. 19, 6902-6906 (2009).
82. J. B. Kevin, E. Chow, H. Xu, R. O. Dror, M. P. Eastwood, B. A. Gregersen, J. L. Klepeis, I. Kolossváry, M. A. Moraes, F. D. Sacerdoti, J. K. Salmon, Y. Shan, D. E. Shaw, Scalable algorithms for MD simulations on commodity clusters, in Proceedings of the ACM/IEEE Conference on Supercomputing (SC06), Tampa, Florida, 11 to 17 November 2006.
83. Acknowledgments: We thank H. Tannoury, J. Y. Park, and J. Rosa for their generous help and discussions with the cell-based assays; T. D. Y. Chung, S. Vasile, E. Sergienko, and the staff of Conrad Prebys Center for Chemical Genomics at the Burnham Institute for Medical Research; and C. Shamu and the staff of the Institute for Chemistry and Chemical Biology at Harvard Medical School for their generous support in the implementation of the HTS assay. We thank S. Shankland and J. Pippin for the gift of sheep antibody against rabbit GBM. We thank M. A. Arnaout, P. Mundel, and D. Stoub for helpful discussions. We also thank Y. Wei and D. Mateu for help with the rat balloon injury model and immunostaining procedures. Funding: This work was supported in part by K01-HL096413 (to R.I.V.-P.) and with resources from the Miller School of Medicine, the Katz Family Fund, and the Center for Computational Science at the University of Miami. Author contributions: D.M. and M.H.F. contributed equally to this work and performed most of the experiments in this study, with technical assistance from C.J.B. and M.D. C.W. performed the anti-GBM nephritis experiment; Y.K. performed the intravital microscopy experiment; K.M.B. and G.L. performed the zebrafish experiments; D.H., A.N., and P.R. conducted the histological analyses; R.I.V.-P. conducted the balloon injury experiment; L.F.M., S.S., D.T., R.I.V.-P., K.L., J.R., and V.G. designed the experiments; L.F.M., D.T., K.L., and J.R. provided input in the preparation of the manuscript; and D.M., M.H.F., J.R., and V.G. co-wrote the paper. Competing interests: V.G. is an inventor of pending patents related to the study, and V.G. and the University of Miami have the potential for financial benefit from their future commercialization. The pending patents have been licensed to Adhaere Pharmaceuticals Inc., a company cofounded by V.G. The authors have no additional financial interests.